Biotech Lead Generation for Suppliers: Find Buyers on LinkedIn
Biotech lead generation for suppliers starts with who evaluates what you sell – process development and quality for a manufacturing partner, clinical operations for a CRO, the lab manager or principal investigator for instruments. LinkedIn is where you find those people at each company, read what they work on and post about, and send a short note tied to your own results.
This guide is about B2B lead generation for biotech: suppliers selling to biotech and pharma companies – CDMOs, CROs, instrument and reagent makers, life-science software vendors. It is not about "lead generation" in drug discovery, and not about marketing to doctors.
The short version. Start from what you sell – the evaluator for a manufacturing partner is not the evaluator for a reagent or a lab system. Read the programme team, not the org chart: at a small spin-out the founders evaluate, at a larger biotech the function leads do. Use conferences as dated windows – a post about a meeting is context, not proof they will buy. Bring your own triggers: funding, trials and grants come from your own sources, and LinkedIn adds the people and what they post. An AI agent can do the reading on your own LinkedIn account and draft notes you approve before anything is sent.
Pharma and biotech on LinkedIn: read the programme team
The agent works through Linked API on your own LinkedIn account, in a real cloud browser at a human pace – Linked API never stores your password. Connect it through the MCP server in Claude, ChatGPT or Cursor, give a coding agent the agent-friendly CLI, or install ready-made skills; the LinkedIn AI agent guide covers the setup.
Used Linked API: search_companies, fetch_company, fetch_person, check_connection_status
- keyword "gene therapy", Biotechnology Research or Pharmaceutical Manufacturing, headquartered in Massachusetts, 51–200 and 201–500 employees, up to 20: 16 companies
- employees titled "process development"
- employees titled "CMC"
- employees titled "technical operations"
- the three passes deduplicated: 13 people at 10 companies; 6 companies with no matching title
- current role, company and recent posts
- 2 already connected
16 companies; 13 people at 10 of them; 6 companies held – no matching title found in these searches. 11 notes drafted, 2 people you're already connected to. Nothing has been sent. The first rows:
| Company | On LinkedIn | Person and title | From the profile or posts | Connected? | Draft note |
|---|---|---|---|---|---|
| Northbridge Gene Therapeutics | 140 members | Elena V., Head of Process Development | Her post about moving from adherent to suspension HEK293 | No | "Hi Elena – saw your post on moving to suspension HEK293. We took a gene therapy team from a research-grade AAV process to its first GMP lot; happy to compare notes." |
| Harborline Bio | 260 members | Raj M., Director, CMC | His post on full/empty capsid analytics | No | "Hi Raj – your post on full/empty capsid analytics caught my eye. We recently took a 120-person gene therapy company to its first GMP lot. Glad to connect." |
| Cedarpoint Therapeutics | 95 members | Tom K., VP Technical Operations | Already connected | Yes | Message instead of a connection request |
| Quarry Hill Genomics | 70 members | – | No matching title found in these searches | – | Held |
nothing goes out until you approve
The run uses the two industry labels most biotech and pharma companies file under on LinkedIn – Biotechnology Research and Pharmaceutical Manufacturing. CROs have no label of their own, so search them by keyword. The exact labels for other segments are in the LinkedIn industry list.
Each note leans on something the person actually wrote, plus the result you supplied – nothing the agent couldn't read. Titles and companies come from each person's profile and member counts from the company page. On a free LinkedIn account only up to three invitations a month can carry a personalised note (LinkedIn Help), so with more drafts than that, send the rest without a note and use the text once they accept.
Who evaluates depends on what you sell
| What you sell | Who usually evaluates | Who else should be in it | What to bring |
|---|---|---|---|
| Manufacturing (CDMO) | Head of process development, CMC lead, head of technical operations | Quality – bring them in early; procurement at larger companies | A comparable process you ran, timelines, capacity |
| Clinical services (CRO) | Clinical operations, outsourcing | Quality management, procurement | Comparable studies in the same therapeutic area |
| Lab instruments and reagents | Lab manager, principal investigator | Procurement; grant rules at academic labs | Data from a comparable lab, a demo |
| Life-science software | Varies – lab informatics, research IT, the scientists who use it | Quality assurance for validated (GxP) systems | A validation package, references |
The titles are common practice, not a measured split. A few sources bound parts of the table:
- Manufacturing. For commercial manufacturing, the FDA's guidance on contract manufacturing quality agreements (2016) says "the owner's quality unit is legally responsible for approving or rejecting drug products manufactured by the contract facility, including for final release." That guidance covers commercial CGMP manufacturing and excludes investigational and clinical-trial materials – so bringing quality into a supplier evaluation earlier is our recommendation, not a legal rule for every purchase. In ISR's tracking of CDMO selection criteria for biologic drug-substance manufacturing (published 2025, results 2020–2023, mainly large and midsize biopharma in North America and Western Europe; sample size not stated), reliable on-time delivery and capacity rose to the top "Most Important" attributes by 2023.
- Clinical services. For clinical-trial service providers, ICH E6(R3) (2025) says "The sponsor is responsible for assessing the suitability of and selecting the service provider to ensure that they can adequately undertake the activities transferred to them." In a study of 18 large German pharma companies (Hennig et al., 2017), the departments involved in choosing a preferred provider were procurement, quality management and clinical research. And in ISR's report in Life Science Leader (November 2022; 58 respondents from small and emerging sponsors), 9% of those respondents reported formal preferred-provider agreements for Phase 2/3 services, against 84% of respondents from large sponsors ($1B+ annual R&D spend).
- Lab instruments. In Lab Manager's reader survey (2022), a new technology purchase "is typically initiated by the lab manager or primary researcher making a request or proposal".
To map everyone else around a deal, see how to map a B2B buying committee.
Stage changes who you talk to
At a 15–20-person spin-out, the founders and the chief scientific officer usually are the evaluators – and LinkedIn's decision-maker list, which is ranked by seniority, is the right list to read. At a 150-person biotech the same list returns the CEO, CSO, chief medical officer and CFO first, while the people who will run your project sit a level or two below. That is why the run above searches each company's employees by function title instead.
Conference windows
Meetings give you a dated reason to look. The next ones, per their organisers: ASHG 2026 ran October 20–24 in Montreal, and ASHG 2027 is October 26–30 in Nashville; SLAS2027 runs January 30 – February 3 in San Diego; AACR 2027 April 2–7 in Orlando; BIO 2027 June 7–10 in Philadelphia. In the organiser's SLAS2027 exhibitor prospectus, 25% selected sourcing new suppliers as an objective; the sample size is not stated.
Here is the same idea for a genomics-tools or bioinformatics vendor, a few weeks after ASHG:
Used Linked API: search_posts, fetch_person
- "ASHG", past month, author industry Biotechnology Research, up to 50: 50 posts
- post text and date checked: 29 mention ASHG 2026 within the window – LinkedIn widens narrow searches, so the rest didn't match
- 24 of those by people rather than company pages, deduplicated to 21 profiles; all 21 pass the headline check
- current company and recent posts
21 people whose own posts mention ASHG 2026. 7 said they presented a talk or poster, 3 said they were looking for something specific. Nothing drafted. The first rows:
| Person | Headline | What the post says | Company (from the profile) | Connection |
|---|---|---|---|---|
| Dana S. | Senior Scientist, Computational Genomics | Said she presented a poster on long-read variant calling | Brightwater Bio | 2nd |
| Marco L. | Director, Bioinformatics | Said the team is looking for a better way to manage sequencing data at scale | Lumen Therapeutics | 3rd+ |
| Aisha K. | Sequencing Lab Manager | Said she gave a talk on single-cell workflows | Harborline Bio | 2nd |
For a CDMO the same window is BIO; for an oncology tools vendor, AACR. More on how post search behaves is in the LinkedIn post scraper guide.
Bring your own triggers
Funding rounds, trial registrations and phase changes, grants and publications are what this market watches – and Linked API does not supply any of them. Bring the company names from your own sources, such as Crunchbase, ClinicalTrials.gov or NIH RePORTER. The agent finds each company's LinkedIn page – check the headquarters and industry, because namesakes exist – and runs the same team read.
Hiring is a hint you can read on LinkedIn. A process-development or quality-control posting can mean a programme moving toward the clinic – or a backfill, or a team building in-house what it used to outsource. Treat it as a reason to look, never as a claim. The LinkedIn jobs guide covers job search itself.
"Won't every AI note sound the same?"
Salesmotion warns that biotech buyers get "dozens of AI-generated messages, all referencing the same LinkedIn profile data". It is a fair warning, and the run above is built around it:
- The note hangs on what the person wrote – a recent post or a stated process problem – plus your specific case, not on a headline anyone could read.
- Rows with nothing specific are held, not filled with a generic compliment.
- You approve every note before it goes.
Agent research for life-science sellers is not new – Succession publishes agent guides for it, and Miniloop's life-sciences playbook covers LinkedIn targeting and note rules. What this guide adds is the concrete run on your own LinkedIn account, with held rows and approval built in.
What to send, and when to follow up
Keep the first note short and about their work, with one line of your proof. Patterns by supplier type – editorial guidance, filled with your own facts:
- CDMO: "Saw your post on [process step]. We took [a comparable company] from [starting point] to [milestone]; happy to compare notes."
- CRO: "Noticed [their programme or post]. We recently ran [a comparable study]; glad to connect."
- Instruments and reagents: "Your talk on [topic] at [meeting] was interesting – we work with labs doing [the same method]."
- Software: "Saw you're scaling [data or workflow problem]. We helped [a comparable team] with [result]."
Follow up once, after a per-person check: have the agent load that person's conversation once, then read it before you write again. An empty result means nothing has been captured yet – not that they didn't reply. One follow-up is this guide's workflow, not a rule from data. More note patterns are in the connection request message guide, and lead qualification covers what to do with a reply.
Expect a long road. Public companies selling instruments and software into this market describe it in their annual reports – Schrödinger: "our sales cycles can be as long as nine to twelve months or longer"; Veeva: "may span 12 months or longer". Those are their words about their own sales, not a benchmark.
What this does not do
- Funding, pipeline and trial data – no funding rounds, trial phases or IND status.
- Publications, patents and grants – none; neither conference speaker nor attendee lists.
- Technographics – which instruments, LIMS or ELN a lab runs, or which CRO or CDMO it already uses.
- Emails and phone numbers – none.
- Site-level location – company search matches headquarters only.
- Automatic watching – signals are coming soon, not available yet; you re-run searches yourself.
- Sequences – no scheduled follow-ups or automatic stop on reply.
Frequently Asked Questions (FAQ)
Through referrals, partnering meetings, conferences and outbound. LinkedIn helps with the outbound part: finding the people who evaluate your service at each company and reading what they work on before you write.
It depends on what you sell. For manufacturing, process development, CMC and technical operations, with quality brought in early; for clinical services, clinical operations and outsourcing; for instruments, the lab manager or principal investigator. At a small spin-out, the founders.
Many scientists keep a LinkedIn profile, but how active they are varies, and bench scientists tend to post less than business development and leadership. Expect some held rows, and lean on people who do post.
Schrödinger describes software sales cycles of nine to twelve months or longer; Veeva says a new-customer sales cycle may span 12 months or longer. These are company-stated examples, not a benchmark for selling to biotech.
On a free account, up to three a month can carry a personalised note, each up to 200 characters; Premium members can add a note to every invitation. An older LinkedIn help page still says five.
In drug discovery, "lead generation" is the hit-to-lead stage of finding candidate molecules – a different topic from this guide.
Build it in, or hand it to an agent
Get it out of the box: connect the MCP server, the agent-friendly CLI or a ready-made skill, and ask in plain language. Or build it into your own tools with the REST API, the Node and Python SDKs and the shell CLI. Either way it runs on your own LinkedIn account. Plans are flat per seat, from $49/mo billed annually – see pricing. For the general agent prospecting loop, see AI sales prospecting on LinkedIn.
Facts verified November 6, 2026 – regulatory text, survey findings, annual-report statements and conference dates checked against the cited FDA, ICH, ISR, Lab Manager, SLAS, AACR, BIO, ASHG and SEC pages; Miniloop, Succession and Salesmotion pages read on that date.